In vitro activity of sitafloxacin against clinical isolates in 2009

Japanese Journal of Antibiotics

Volumn 63, Issue 6, 2010, Pages 411-430

  Amano, Ayako ^a   Matsuzaki, Kaoru ^a   Kishi, Naoko ^a   Saika, Takeshi ^a   Hasegawa, Miyuki ^a   Ikeda, Fumiaki ^a   Matsumoto, Takuyuki ^b   Yamaguchi, Hiroki ^b   Kanda, Yuko ^b   Shiozawa, Tomoo ^b  

^a LSI MEDIENCE CORPORATION   (Japan)

^b DAIICHI SANKYO CO   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

GARENOXACIN; LEVOFLOXACIN; MOXIFLOXACIN; SITAFLOXACIN;

ANTIBIOTIC SENSITIVITY; ANTIMICROBIAL ACTIVITY; ARTICLE; BACTERIAL GROWTH; BACTERIUM ISOLATE; DRUG ACTIVITY; ENTEROCOCCUS FAECALIS; ESCHERICHIA COLI; HAEMOPHILUS INFLUENZAE; IN VITRO STUDY; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MINIMUM INHIBITORY CONCENTRATION; MORAXELLA CATARRHALIS; NONHUMAN; PSEUDOMONAS AERUGINOSA; STREPTOCOCCUS PNEUMONIAE; STREPTOCOCCUS PYOGENES;

ANTI-BACTERIAL AGENTS; BACTERIA, ANAEROBIC; FLUOROQUINOLONES; GRAM-NEGATIVE BACTERIA; GRAM-POSITIVE BACTERIA; MICROBIAL SENSITIVITY TESTS;

EID: 79551574812     PISSN: 03682781     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (15)

1. KANAYAMA, A.; T. IYODA, K. MATSUZAKI, et al.: Rapidly spreading CTX-M-type β-lactamase-producing Proteus mirabilis in Japan. Int. J. Antimicrob. Agents 36: 340-342, 2010
2. Clinical and Laboratory Standards Institute: Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; Approved standard - seventh edition. M7-A7. Wayne, PA, 2006
3. Clinical and Laboratory Standards Institute: Performance standards for antimicrobial susceptibility testing; eighteenth informational supplement M100-S18. Wayne, PA, 2008
4. Clinical and Laboratory Standards Institute: Methods for antimicrobial susceptibility testing of anaerobic bacteria; Approved standard - seventh edition. M11-A7. Wayne, PA, 2007
5. UBUKATA, K.: Problems associated with high prevalence of multidrug-resistant bacteria in patients with community-acquired infections. J. Infect. Chemother. 9: 285-291, 2003
6. QIN, L.; H. WATANABE, N. ASOH, et al.: Antimicrobial susceptibility and genetic characteristics of Haemophilus influenzae isolated from patients with respiratory tract infections between 1987 and 2000, including β-lactamase-negative ampicillin-resistant strains. Epidemiol. Infect. 135: 665-668, 2007
7. YAMAGUCHI, K.; A. OHNO & Levofloxacin Surveillance Group: Investigation of the susceptibility trends in Japan to fluoroquinolones and other antimicrobial agents in a nationwide collection of clinical isolates: A longitudinal analysis from 1994 to 2002. Diagn. Microbiol. Infect. Dis. 52: 135-143, 2005
8. HOOPER, D. C.: Mechanisms of action of antimicrobials: Focus on fluoroquinolones. Clin. Infect. Dis. 32 (Suppl. 1): S9-S15, 2001
9. HAWKEY, P. M. & A. M. JONES: The changing epidemiology of resistance. J. Antimicrob. Chemother. 64 (Suppl. 1): i3-i10, 2009
10. AKASAKA, T.; M. TANAKA, A. YAMAGUCHI, et al.: Type II topoisomerase mutations in fluoroquinolone-resistant clinical strains of Pseudomonas aeruginosa isolated in 1998 and 1999: Role of target enzyme in mechanism of fluoroquinolone resistance. Antimicrob. Agents Chemother. 45: 2263-2268, 2001
11. OKUMURA, R.; T. HIRATA, Y. ONODERA, et al.: Dual-targeting properties of the 3-amino-pyrrolidyl quinolones, DC-159a and sitafloxacin, against DNA gyrase and topoisomerase IV: Contribution to reducing in vitro emergence of quinolone-resistant Streptococcus pneumoniae. J. Antimicrob. Chemother. 62: 98-104, 2008